Spots Global Cancer Trial Database for A Study of AMG 820 in Subjects With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of AMG 820 in Subjects With Advanced Solid Tumors
Official Title: A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics of AMG 820 in Adult Subjects With Advanced Solid Tumors
Study ID: NCT01444404
Interventions
Study Description
Brief Summary: First in human, open-label, sequential dose escalation and expansion study of AMG 820 in subjects with advanced solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Philadelphia, Pennsylvania, United States
Research Site, Greenville, South Carolina, United States
Research Site, San Antonio, Texas, United States
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
